Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Fluxion Biosciences Introduces IsoFlux™ NGS Assay Kits

Published: Tuesday, April 22, 2014
Last Updated: Monday, April 21, 2014
Bookmark and Share
New kits enable mutation detection from circulating tumor cells using next-generation sequencing.

Fluxion Biosciences has announced the introduction of a new series of assay kits design to enhance and complete the workflow for next-generation sequencing (NGS) using the IsoFlux System.

The IsoFlux™ NGS assay kits are designed to work with circulating tumor material enriched on the IsoFlux System. They significantly increase the overall target purity of the sample and provide a robust nucleic acid extraction method that is optimized for next-generation sequencing.

The IsoFlux NGS assay kits are available for immediate use through the IsoFlux Discovery Services program, with kit shipments to IsoFlux customers starting in June 2014.

Circulating tumor cells (CTCs) enable access to tumor material without the need for a surgical biopsy. CTCs possess the key advantage of being able to be enriched over the background blood cells, making it possible to analyze them using molecular methods.

Other approaches to obtaining tumor material from the circulation, such as cell-free DNA, have limitations in this regard. Despite recent advances in CTC technologies, it remains a persistent challenge to enrich sufficiently to meet the rigorous requirements of next-generation sequencing platforms.

The IsoFlux NGS assay kits incorporate a proprietary method of purity enhancement that, when combined with the IsoFlux System for primary enrichment, delivers a high purity DNA or RNA sample immediately ready for next-generation sequencing.

Next-generation sequencing plays an essential role in the emerging field of precision medicine. Clinical scientists have utilized NGS to learn how and why patients may respond or fail to particular therapies. They can employ NGS to learn how to best predict which therapies a patient might respond to over time.

Timely access to tumor material has been the primary limitation to this approach. Serial tissue biopsy is not generally practiced due to the high risks, high costs, and limited success rates.

The IsoFlux NGS kits provide a valuable tool to clinical scientists and drug developers to track the course of disease for an individual patient and as part of broader research studies.

The IsoFlux NGS kits have been developed and validated with leading commercial NGS platforms and cancer mutation panels ranging from 5 to 500 genes of interest to cancer.

“The IsoFlux NGS assay kits deliver on the promise of where precision medicine is heading,” said Jeff Jensen, CEO at Fluxion. “The ability to analyze a broad range of cancer biomarkers in a single blood-based test provides critical information that will help inform the next generation of targeted therapies and diagnostics.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluxion Biosciences to Distribute Millipore PrecisION® Ion Channel Cell Lines
Combination with IonFlux™ automated patch clamp system creates a validated, affordable solution for ion channel profiling and screening.
Thursday, December 22, 2011
Ohio State University Researchers Adopt IonFlux 16 Automated Patch Clamp System
First of kind high throughput instrument for research applications enables ion channel studies.
Monday, August 16, 2010
Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos